(Q43056152)

13 November 2017

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models (English)

1 reference

13 November 2017

Gregory D Plowman

19

0 references

author name string

Mallika Singh

1

1 reference

13 November 2017

Anthony Lima

2

1 reference

13 November 2017

Rafael Molina

3

1 reference

13 November 2017

Patricia Hamilton

4

1 reference

13 November 2017

Anne C Clermont

5

1 reference

13 November 2017

Vidusha Devasthali

6

1 reference

13 November 2017

Jennifer D Thompson

7

1 reference

13 November 2017

Jason H Cheng

8

1 reference

13 November 2017

Hani Bou Reslan

9

1 reference

13 November 2017

Calvin C K Ho

10

1 reference

13 November 2017

Timothy C Cao

11

1 reference

13 November 2017

Chingwei V Lee

12

1 reference

13 November 2017

Michelle A Nannini

13

1 reference

13 November 2017

Germaine Fuh

14

1 reference

13 November 2017

Richard A D Carano

15

1 reference

13 November 2017

Hartmut Koeppen

16

1 reference

13 November 2017

Ron X Yu

17

1 reference

13 November 2017

William F Forrest

18

1 reference

13 November 2017

Leisa Johnson

20

1 reference

13 November 2017

23 May 2010

1 reference

13 November 2017

1 reference

13 November 2017

28

1 reference

13 November 2017

585-593

1 reference

13 November 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt.1640

13 November 2017

0 references

cites work

A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model.

1 reference

12 December 2020

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

1 reference

12 December 2020

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma

1 reference

12 December 2020

High-resolution X-ray microtomography for the detection of lung tumors in living mice

1 reference

12 December 2020

The differential effects of mutant p53 alleles on advanced murine lung cancer

1 reference

12 December 2020

Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?

1 reference

12 December 2020

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Genetically engineered models have advantages over xenografts for preclinical studies

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

1 reference

12 December 2020

Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.

1 reference

12 December 2020

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

1 reference

12 December 2020

A new generation of mouse models of cancer for translational research

1 reference

12 December 2020

The Catalogue of Somatic Mutations in Cancer (COSMIC)

1 reference

12 December 2020

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

1 reference

12 December 2020

Random-effects models for longitudinal data

1 reference

12 December 2020

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

1 reference

12 December 2020

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

1 reference

12 December 2020

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Simultaneous inference in general parametric models

1 reference

12 December 2020

Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models

1 reference

12 December 2020

Mutations and response to epidermal growth factor receptor inhibitors

1 reference

12 December 2020

Oncogenes come of age.

1 reference

12 December 2020

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

12 December 2020

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer

1 reference

12 December 2020

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

12 December 2020

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

12 December 2020

Endpoints for assessing drug activity in clinical trials

1 reference

12 December 2020

Using genetically engineered mouse models of cancer to aid drug development: an industry perspective

1 reference

12 December 2020

Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo

1 reference

12 December 2020

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

12 December 2020

Cancer modeling in the modern era: progress and challenges

1 reference

12 December 2020

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

12 December 2020

Tumor-suppressive pathways in pancreatic carcinoma.

1 reference

12 December 2020

EGFR antagonists in cancer treatment

1 reference

12 December 2020

Blocking neuropilin-2 function inhibits tumor cell metastasis

1 reference

12 December 2020

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

1 reference

12 December 2020

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

12 December 2020

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

1 reference

12 December 2020

K‐Ras‐Driven Pancreatic Cancer Mouse Model for Anticancer Inhibitor Analyses

1 reference

12 December 2020

Determinants of RASistance to anti-epidermal growth factor receptor agents

1 reference

12 December 2020

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer

1 reference

12 December 2020

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

1 reference

12 December 2020

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

1 reference

12 December 2020

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

1 reference

12 December 2020

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)

1 reference

12 December 2020

Gastrosplenic fistula from Hodgkin's lymphoma

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNBT.1640

7 January 2021

inferred from DOI database lookup

The Efficiency of Cox's Likelihood Function for Censored Data

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNBT.1640

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NBT.1640

1 reference

13 November 2017

1 reference